PANBIO
LIVE

Add to watchlist:

No watchlists yet
View on USPTO

PANBIO Trademark

Serial Number: 79285587 • Registration: 6375117

PANBIO is a trademark filed by Abbott Rapid Diagnostics International Subsidiary Unlimited Company on April 8, 2020. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals). The application is currently registered and active.

Owner Contact Info

Trademark Details

Filing Date

April 8, 2020

Registration Date

June 8, 2021

Published for Opposition

March 23, 2021

Goods & Services

Diagnostic kits comprising medical diagnostic bioreagents for testing blood, bodily fluid, nasal samples, oral samples and tissue for use in the detection, identification, confirmation, and monitoring of respiratory, community acquired, hospital acquired, sexual health, gastro-enteric, vector borne, blood borne pathogen, and tropical disease infections; medical diagnostic test kits consisting primarily of monoclonal antibodies, buffers, and reagents for use in disease testing; medical diagnostic test strips for testing blood, human serum, plasma, bodily fluid, nasal swab specimens, nasopharyngeal swab specimens, oral specimens, oropharyngeal swab specimens, and tissue for use in the detection, identification, confirmation, and monitoring of respiratory, community acquired, hospital acquired, sexual health, gastro-enteric, vector borne, blood borne pathogen, and tropical disease infections; medical diagnostic reagents; diagnostic preparations for medical purposes; testing preparations for medical use, namely, diagnostic preparations; diagnostic tests for medical use, namely, medical diagnostic test media in the form of strips, cassettes, cartridges, and cards for the detection, identification, confirmation, and monitoring of respiratory, community acquired, hospital acquired, sexual health, gastro-enteric, vector borne, blood borne pathogen, and tropical disease infections; medical diagnostic assays for testing of body fluids, blood, human serum, plasma, nasal swab specimens, nasopharyngeal swab specimens, oral specimens, oropharyngeal swab specimens, and tissue; in vitro medical diagnostic tests, namely, medical diagnostic test media in the form of strips, cassettes, cartridges, and cards for the detection, identification, confirmation, and monitoring of respiratory, community acquired, hospital acquired, sexual health, gastro-enteric, vector borne, blood borne pathogen, and tropical disease infections; in vitro medical diagnostic assays for testing of body fluids, blood, human serum, plasma, nasal swab specimens, nasopharyngeal swab specimens, oral specimens, oropharyngeal swab specimens, and tissue; in vitro medical diagnostic test kits consisting primarily of monoclonal antibodies, buffers, and reagents for use in disease testing; in vitro medical diagnostic test strips for use in the field of infectious disease; in vitro medical diagnostic reagents; in vitro immunochromatographic tests for medical use, namely, medical diagnostic reagents and assays for testing of body fluids, blood, human serum, plasma, nasal swab specimens, nasopharyngeal swab specimens, oral specimens, oropharyngeal swab specimens, and tissue; medical diagnostics tests for the detection, diagnosis, screening, and confirmation of infections, namely, medical diagnostic reagents and assays for testing of body fluids, blood, human serum, plasma, nasal swab specimens, nasopharyngeal swab specimens, oral specimens, oropharyngeal swab specimens, and tissue

Control preparations for in vitro diagnostic testing, screening, confirmation and analysis, namely, diagnostic preparations for scientific or research use; diagnostic reagents and chemical reagents for laboratory or research purposes; chemical reagents, namely, solutions used in diagnostic test kits for laboratory or research purposes; chemically-treated nonmedical test strips for laboratory or research purposes for testing for respiratory, community acquired, hospital acquired, sexual health, gastro-enteric, vector borne, blood borne pathogen, and tropical disease infections; diagnostic test kits comprised of reagents for use in diagnostic tests for laboratory or research use; diagnostic preparations for laboratory or research use; diagnostic test kits comprising reagents and assays for laboratory or research use; in vitro diagnostic tests, namely, chemical reagents and assays for testing for respiratory, community acquired, hospital acquired, sexual health, gastro-enteric, vector borne, blood borne pathogen, and tropical disease infections for laboratory or research use, other than for medical or veterinary use; in vitro immunochromatographic tests, namely, chemical reagents and assays for testing for respiratory, community acquired, hospital acquired, sexual health, gastro-enteric, vector borne, blood borne pathogen, and tropical disease infections for laboratory or research use, other than for medical or veterinary use

Filing History

NEW REPRESENTATIVE AT IB RECEIVED
Jan 3, 2025 NREP
NEW REPRESENTATIVE AT IB RECEIVED
Jan 5, 2024 NREP
FINAL DECISION TRANSACTION PROCESSED BY IB
Nov 15, 2021 FINO
GENERIC MADRID TRANSACTION SENT TO IB
Sep 28, 2021 XXSS
GENERIC MADRID TRANSACTION CREATED
Sep 28, 2021 XXCR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Sep 8, 2021 FICR
REGISTERED-PRINCIPAL REGISTER
Jun 8, 2021 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Mar 23, 2021 NPUB
PUBLISHED FOR OPPOSITION
Mar 23, 2021 PUBO
NOTIFICATION PROCESSED BY IB
Mar 21, 2021 GPNX
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Mar 3, 2021 OPNS
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Mar 3, 2021 OP2R
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Mar 3, 2021 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Feb 16, 2021 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Feb 9, 2021 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Feb 8, 2021 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Feb 8, 2021 TROA
REFUSAL PROCESSED BY IB
Aug 25, 2020 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Aug 6, 2020 RFCS
REFUSAL PROCESSED BY MPU
Aug 6, 2020 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Jul 1, 2020 RFCR
NON-FINAL ACTION WRITTEN
Jun 30, 2020 CNRT
ASSIGNED TO EXAMINER
Jun 25, 2020 DOCK
APPLICATION FILING RECEIPT MAILED
May 19, 2020 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
May 15, 2020 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
May 14, 2020 REPR